EcoDrugPlus

Phosphoribosylglycinamide Formyltransferase

Ensembl ID : ENSORLG00000006275
Gene Symbol: GART
4 Cross references
246 Possible Orthologues:

Plasminogen Activator, Tissue

Ensembl ID : ENSORLG00000002355
Gene Symbol: PLAT
3 Cross references
205 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSORLG00000023527
Gene Symbol: PTAFR
4 Cross references
221 Possible Orthologues:

Platelet Derived Growth Factor Subunit B

Ensembl ID : ENSORLG00000030121
Gene Symbol: SI:CH211-79M20.1
3 Cross references
190 Possible Orthologues:

Platelet-Activating Factor Receptor-Like

Ensembl ID : ENSORLG00000024944
Gene Symbol: LOC101159308
3 Cross references
221 Possible Orthologues:

Platelet-Derived Growth Factor Beta Polypeptide B

Ensembl ID : ENSORLG00000013411
Gene Symbol: PDGFBB
3 Cross references
196 Possible Orthologues:

Platelet-Derived Growth Factor Receptor Beta

Ensembl ID : ENSORLG00000012831
Gene Symbol: LOC101156428
3 Cross references
174 Possible Orthologues:

Platelet-Derived Growth Factor Receptor, Alpha Polypeptide

Ensembl ID : ENSORLG00000019815
Gene Symbol: PDGFRA
4 Cross references
203 Possible Orthologues:

Platelet-Derived Growth Factor Receptor, Beta Polypeptide

Ensembl ID : ENSORLG00000004786
Gene Symbol: PDGFRB
4 Cross references
198 Possible Orthologues:

Polo Like Kinase 1

Ensembl ID : ENSORLG00000009603
Gene Symbol: PLK1
4 Cross references
188 Possible Orthologues:

Polo-Like Kinase 4 (Drosophila)

Ensembl ID : ENSORLG00000015971
Gene Symbol: PLK4
4 Cross references
215 Possible Orthologues:

Poly (Adp-Ribose) Polymerase 1

Ensembl ID : ENSORLG00000013691
Gene Symbol: PARP1
4 Cross references
209 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).